Fusafungine
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | R02AB03 (WHO) |
| Identifiers | |
| Synonyms | Fusafungin |
| CAS Number |
1393-87-9  |
| DrugBank |
DB08965  |
| UNII |
65DD690W0C |
| KEGG |
D08002 |
| ECHA InfoCard | 100.014.306 |
| Chemical and physical data | |
| Formula | C29H51N2O8 |
| Molar mass | 555.72 g/mol[1] |
| (what is this?) (verify) | |
Fusafungine (INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L-N-methylamino acid residues,[2] produced by the ascomycete Fusarium lateritium, and marketed by Servier under the trade names Locabiotal, Bioparox, and Locabiosol.
According to a pooled analysis study done in the UK for the efficacy of fusafungine in rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.[3]
In February 2016, the European Medicines Agency recommended to withdraw fusafungine from the market due to rare but severe allergic reactions (mainly bronchospasms).[4]
References
- ↑ Fusafungine at MeSH
- ↑ Daniel Levy; Aline Bluzat; Michel Seigneuret; Jean-Louis Rigaud (1995). "Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins". Biochemical Pharmacology. 50 (12 22): 2105–2107. doi:10.1016/0006-2952(95)02045-4. PMID 8849339.
- ↑ Lund, V. J.; Grouin, J. M.; Eccles, R; Bouter, C; Chabolle, F (2004). "Efficacy of fusafungine in acute rhinopharyngitis: A pooled analysis". Rhinology. 42 (4): 207–12. PMID 15626253.
- ↑ PRAC recommends that fusafungine nose and mouth sprays are no longer marketed